|
[1] Polaris Observatory Collaborators. Global prevalence,treatment,and prevention of hepatitis B virus infection in 2016:A modelling study[J]. Lancet Gastroenterol Hepatol,2018,3(6):383-403.
|
|
[2] FLORES R,RUIZ-RUIZ S,SERRA P. Viroids and hepatitis delta virus[J]. Semin Liver Dis,2012,32(3):201-210.
|
|
[3] SHIRVANI-DASTGERDI E,TACKE F. Molecular interactions between hepatitis B virus and delta virus[J]. World J Virol,2015,4(2):36-41.
|
|
[4] DENY P. Hepatitis delta virus genetic variability:From genotypes I,II,III to eight major clades?[J]. Curr Top Microbiol Immunol,2006,307:151-171.
|
|
[5] GAETA GB,STROFFOLINI T,CHIARAMONTE M,et al. Chronic hepatitis D:A vanishing disease? An Italian multicenter study[J]. Hepatology,2000,32(4 Pt 1):824-827.
|
|
[6] HEIDRICH B,DETERDING K,TILLMANN HL,et al. Virological and clinical characteristics of delta hepatitis in Central Europe[J]. J Viral Hepat,2009,16(12):883-894.
|
|
[7] PATEL EU,THIO CL,BOON D,et al. Prevalence of hepatitis B and hepatitis D virus infections in the United States,2011-2016[J]. Clin Infect Dis,2019,69(4):709-712.
|
|
[8] RIZZETTO M,CIANCIO A. Epidemiology of hepatitis D[J].Semin Liver Dis,2012,32(3):211-219.
|
|
[9] HAO LJ,LI L,ZHANG YY,et al. Hepatitis D virus infection in liver tissues of patients with hepatitis B in China[J]. Chin Med J(Engl),1992,105(3):204-208.
|
|
[10] HUO TI,WU JC,LAI CR,et al. Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection[J].J Hepatol,1996,25(4):439-444.
|
|
[11] CROSS TJ,RIZZI P,HORNER M,et al. The increasing prevalence of hepatitis delta virus(HDV)infection in South London[J]. J Med Virol,2008,80(2):277-282.
|
|
[12] TOUKAN AU,ABU-EL-RUB OA,ABU-LABAN SA,et al.The epidemiology and clinical outcome of hepatitis D virus(delta)infection in Jordan[J]. Hepatology,1987,7(6):1340-1345.
|
|
[13] TAMURA I,KURIMURA O,KODA T,et al. Risk of liver cirrhosis and hepatocellular carcinoma in subjects with hepatitis B and delta virus infection:A study from Kure,Japan[J]. J Gastroenterol Hepatol,1993,8(5):433-436.
|
|
[14] FATTOVICH G,GIUSTINA G,CHRISTENSEN E,et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis(Eurohep)[J]. Gut,2000,46(3):420-426.
|
|
[15] UZUNALIMOGˇLU O,YURDAYDIN C,CETINKAYA H,et al.Risk factors for hepatocellular carcinoma in Turkey[J]. Dig Dis Sci,2001,46(5):1022-1028.
|
|
[16] DEGˇERTEKIN H,YALIN K,YAKUT M. The prevalence of hepatitis delta virus infection in acute and chronic liver diseases in Turkey:An analysis of clinical studies[J]. Turk J Gastroenterol,2006,17(1):25-34.
|
|
[17] ROMEO R,DEL NINNO E,RUMI M,et al. A 28-year study of the course of hepatitis delta infection:A risk factor for cirrhosis and hepatocellular carcinoma[J]. Gastroenterology,2009,136(5):1629-1638.
|
|
[18] BUTI M,HOMS M,RODRIGUEZ-FRIAS F,et al. Clinical outcome of acute and chronic hepatitis delta over time:A longterm follow-up study[J]. J Viral Hepat,2011,18(6):434-442.
|
|
[19] JI J,SUNDQUIST K,SUNDQUIST J. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma[J]. J Natl Cancer Inst,2012,104(10):790-792.
|
|
[20] ROMEO R,FOGLIENI B,CASAZZA G,et al. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta[J]. PLo S One,2014,9(3):e92062.
|
|
[21] KUSHNER T,SERPER M,KAPLAN DE. Delta hepatitis within the Veterans Affairs medical system in the United States:Prevalence,risk factors,and outcomes[J]. J Hepatol,2015,63(3):586-592.
|
|
[22] AMOUGOU MA,NOAH DN,MOUNDIPA PF,et al. A prominent role of hepatitis D virus in liver cancers documented in Central Africa[J]. BMC Infect Dis,2016,16(1):647.
|
|
[23] BEGUELIN C,MORADPOUR D,SAHLI R,et al. Hepatitis delta-associated mortality in HIV/HBV-coinfected patients[J].J Hepatol,2017,66(2):297-303.
|
|
[24] BRANCACCIO G,FASANO M,GROSSI A,et al. Clinical outcomes in patients with hepatitis D,cirrhosis and persistent hepatitis B virus replication,and receiving long-term tenofovir or entecavir[J]. Aliment Pharmacol Ther,2019,49(8):1071-1076.
|
|
[25] MAHALE P,AKA P,CHEN X,et al. Hepatitis D virus infection,cirrhosis and hepatocellular carcinoma in The Gambia[J]. J Viral Hepat,2019,26(6):738-749.
|
|
[26] PASCARELLA S,NEGRO F. Hepatitis D virus:An update[J].Liver Int,2011,31(1):7-21.
|
|
[27] SUREAU C,NEGRO F. The hepatitis delta virus:Replication and pathogenesis[J]. J Hepatol,2016,64(1 Suppl):s102-s116.
|
|
[28] CHOI SH,JEONG SH,HWANG SB. Large hepatitis delta antigen modulates transforming growth factor-beta signaling cascades:Implication of hepatitis delta virus-induced liver fibrosis[J]. Gastroenterology,2007,132(1):343-357.
|
|
[29] GUILHOT S,HUANG SN,XIA YP,et al. Expression of the hepatitis delta virus large and small antigens in transgenic mice[J]. J Virol,1994,68(2):1052-1058.
|
|
[30] DIAZ G,ENGLE RE,TICE A,et al. Molecular signature and mechanisms of hepatitis D virus-associated hepatocellular carcinoma[J]. Mol Cancer Res,2018,16(9):1406-1419.
|
|
[31] PHILIPP T,DURAZZO M,TRAUTWEIN C,et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3antibodies in chronic hepatitis D[J]. Lancet,1994,344(8922):578-581.
|
|
[32] WILLIAMS V,BRICHLER S,KHAN E,et al. Large hepatitis delta antigen activates STAT-3 and NF-κB via oxidative stress[J]. J Viral Hepat,2012,19(10):744-753.
|
|
[33] PARK CY,OH SH,KANG SM,et al. Hepatitis delta virus large antigen sensitizes to TNF-alpha-induced NF-kappaB signaling[J]. Mol Cells,2009,28(1):49-55.
|
|
[34] WARIS G,HUH KW,SIDDIQUI A. Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kappa B via oxidative stress[J].Mol Cell Biol,2001,21(22):7721-7730.
|
|
[35] BENEGIAMO G,VINCIGUERRA M,GUARNIERI V,et al. Hepatitis delta virus induces specific DNA methylation processes in Huh-7liver cancer cells[J]. FEBS Lett,2013,587(9):1424-1428.
|
|
[36] LIAO FT,LEE YJ,KO JL,et al. Hepatitis delta virus epigenetically enhances clusterin expression via histone acetylation in human hepatocellular carcinoma cells[J]. J Gen Virol,2009,90(Pt 5):1124-1134.
|
|
[37] LAU SH,SHAM JS,XIE D,et al. Clusterin plays an important role in hepatocellular carcinoma metastasis[J]. Oncogene,2006,25(8):1242-1250.
|
|
[38] ZHANG Q,MATSUURA K,KLEINER DE,et al. Analysis of long noncoding RNA expression in hepatocellular carcinoma of different viral etiology[J]. J Transl Med,2016,14(1):328.
|
|
[39] SORIANO V,VISPO E,SIERRA-ENGUITA R,et al. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients[J]. AIDS,2014,28(16):2389-2394.
|
|
[40] LE GAL F,BRICHLER S,SAHLI R,et al. First international external quality assessment for hepatitis delta virus RNA quantification in plasma[J]. Hepatology,2016,64(5):1483-1494.
|
|
[41] HEIDRICH B,YURDAYDIN C,KABAAM G,et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta[J]. Hepatology,2014,60(1):87-97.
|
|
[42] ETZION O,HAMID S,LURIE Y,et al. End of study results from LIMT HDV study:36%durable virologic response at 24weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection[J]. J Hepatology,2019,70:e32.
|
|
[43] ELAZAR M,GLENN JS. Emerging concepts for the treatment of hepatitis delta[J]. Curr Opin Virol,2017,24:55-59.
|
|
[44] LEONG PL,ANDREWS GA,JOHNSON DE,et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth[J]. Proc Natl Acad Sci U S A,2003,100(7):4138-4143.
|
DownLoad: